Dr. Charles K. Vorkas — a new arrival at Stony Brook’s Renaissance School of Medicine with a diverse background in research and international patient care — is leading efforts in his newly-established lab to better understand disease resistance.
Due to their privatization of data, 23andMe restricts the ability of the research community to make significant progress outside of specific collaborations with the company.
